1. Glucotrack entered a $4 million securities purchase agreement. 2. Company to sell 1,033,591 shares and warrants for $3.87 each. 3. Proceeds will be used for working capital and corporate purposes. 4. Shareholder approval required for warrant exercise. 5. Company developing innovative diabetes monitoring technology.
FAQ
Why Bullish?
The capital raised can enhance R&D for their diabetes technologies, historically driving stock growth in biotech sectors during funding announcements.
How important is it?
The announcement signals financial stability and growth potential, critical for investor outlook.
Why Short Term?
Immediate funding boosts will reflect in upcoming quarterly reports and investor sentiment, affecting short-term price.
Glucotrack, Inc. (NASDAQ: GCTK) Announces $4.0 Million Private Placement
Rutherford, NJ., Dec. 30, 2025 (GLOBE NEWSWIRE) — Glucotrack, Inc. (Nasdaq: GCTK), a leading medical technology company dedicated to developing innovative solutions for diabetes management, has announced a significant financial move. The company has entered into a securities purchase agreement with a single institutional investor, resulting in the sale of 1,033,591 shares of common stock and warrants to purchase up to 2,067,182 additional shares. This deal is expected to generate approximately $4.0 million in gross proceeds.
Details of the Private Placement
The agreement includes an effective combined price of $3.87 per share and common warrant. The warrants issued will not be exercisable until shareholder approval is obtained and will have an exercise price matching the share price of $3.87. They will expire five years from the initial exercise date.
The transaction is projected to close on or around December 31, 2025, subject to the fulfillment of customary closing conditions. Proceeds from this offering are intended for working capital and other general corporate purposes.
Regulatory Information and Conditions
The securities are being offered under an exemption from registration requirements—specifically, under Section 4(a)(2) of the Securities Act of 1933, as amended, and applicable state laws. As such, these securities have not been registered and may not be sold in the United States without an effective registration statement or a suitable exemption.
In line with a registration rights agreement with the institutional investor, Glucotrack is committed to filing a registration statement with the U.S. Securities and Exchange Commission (SEC) to cover the resale of the shares issued. This filing will occur no later than 15 calendar days after the closing and should become effective within 45 days post-closing.
About Glucotrack, Inc.
Glucotrack, Inc. (NASDAQ: GCTK) focuses on designing and commercializing advanced technologies for diabetes management. The company’s flagship product is a long-term implantable continuous blood glucose monitoring system, which allows users to check blood glucose levels without the need for external devices.
The Glucotrack Continuous Blood Glucose Monitor (CBGM) features a sensor that can operate for up to three years, without requiring a wearable component. However, it is important to note that the CBGM is classified as an Investigational Device, limited to investigational use under U.S. federal law.
For further information, visit Glucotrack's official website.
Forward-Looking Statements
This announcement contains forward-looking statements as per the Private Securities Litigation Reform Act of 1995. Terms such as “anticipate,” “believe,” “expect,” and “planning” indicate forward-looking statements, particularly those related to the completion of the offering, intended use of proceeds, and regulatory filings with the SEC.
While these statements reflect management’s beliefs and current information, Glucotrack does not guarantee that these will result in actual outcomes. Risks associated with potential financial performance include regulatory approvals and the ability to conduct clinical trials effectively, among other factors outlined in the company's SEC filings.